Orthocell’s Remplir Exempt from US Tariffs, Deployed in 23 Ukraine Surgeries
Orthocell's Remplir nerve repair device, classified as a medical device, should avoid proposed US Section 232 pharmaceutical tariffs and already has 4,000 units in the US. Early US rollout shows growing hospital uptake and repeat usage, while Remplir has been used in 23 procedures on injured Ukrainian soldiers.
1. Tariff Exemption for Remplir
Orthocell confirmed that Remplir, as a medical device, falls outside the scope of proposed US Section 232 pharmaceutical tariffs, ensuring the company’s margins and pricing strategy remain intact. The company stated that roughly 4,000 units already in-market in the US will not face additional duties, safeguarding its commercial rollout.
2. US Commercial Traction
After years of development, Orthocell has shifted Remplir into active sales in the US, achieving early hospital adoption, surgeon uptake and repeat procedures. These indicators of traction support the company’s US growth strategy in a competitive nerve repair market and suggest scalable revenue potential.
3. Deployment in Ukraine
Following a humanitarian shipment to Ukraine in April 2025, Remplir has been used in 23 surgical procedures on injured soldiers, providing real-world validation of its technology in frontline trauma care. This deployment underscores the device’s clinical utility and may boost confidence in its broader adoption in high-volume nerve repair surgeries.